


REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)



In re Application of

Application Number

08-256631

Filed

12-1-94

Group Art Unit

Examiner

Paper No. 116

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ☐ (A) referred to in United States Patent Number 5871734, column _____.
- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____.
- ☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- ☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Nettie Walker

Signature

N. WALKER

Typed or printed name

Date

3-29-00

FOR PTO USE ONLY

Approved by: [Signature]

(Initials)

Unit: FTD4

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. The time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[54] TREATMENT FOR ASTHMA WITH VLA-4 BLOCKING AGENTS

[75] Inventors: Roy R. Lobb, Westwood; Linda C. Burkly, West Newton, both of Mass.

[73] Assignee: Biogen, Inc., Cambridge, Mass.

[21] Appl. No.: 822,830

[22] Filed: Mar. 21, 1997

Related U.S. Application Data

[63] Continuation of Ser. No. 456,193, May 31, 1995, abandoned, which is a continuation-in-part of Ser. No. 374,331, Jan. 18, 1995, abandoned, which is a continuation-in-part of Ser. No. 256,631, Dec. 1, 1994, abandoned, which is a continuation-in-part of PCT/US93/00030 Jan. 12, 1993, which is a continuation-in-part of Ser. No. 821,768, Jan. 13, 1992, abandoned.

[51] Int. Cl.⁶ A61K 39/395; A61K 35/12; A61K 38/17

[52] U.S. Cl. 424/144.1; 424/130.1; 424/133.1; 424/171.1; 424/143.1; 424/153.1; 424/154.1; 424/173.1; 514/2; 514/8; 514/885

[58] Field of Search 424/130.1, 133.1, 424/143.1, 154.1; 514/387.1, 388.22; 514/2, 8

[56] References Cited

U.S. PATENT DOCUMENTS

4,816,397 3/1989 Boss et al.
4,833,092 5/1989 Geysen
5,116,964 5/1992 Capon
5,272,263 12/1993 Heshon
5,730,978 3/1998 Wayner et al.

FOREIGN PATENT DOCUMENTS

0 330 506 8/1989 European Pat. Off.
387701 9/1990 European Pat. Off.
9103252 3/1991 WIPO
WO 92/00751 1/1992 WIPO
WO 95.19790 1/1995 WIPO

OTHER PUBLICATIONS

McNeil JNCI 87: 1658-1660 (1995).
Issekutz et al. J. Immunol. 147: 109-116 (1991).
Issekutz J. Immunol. 147: 4178-4184 (1991).
Mountain et al. Gen Eng Rev 110:1, 10-13 only (1992).
Edgington Biotechnology 10: 383-389 (1992).
Ward et al. Therapeutic Immunology 1: 165-171 (1994).
McCabe et al. Cell Immunol. 150: 364-375 (1993).
Paul Fundamental Immunol. 3rd Ed. 1993 Raven Press p. 242 only.
Osborn Cell 62: 3-6 1990.
Gundel et al. J Allergy Clin. Immunol. 85: 282 (1990).
Altman, L.K., (1991) "Despite Gains in Treatment, Asthma Worsens", *New York Times*, The Doctor's World, Mar. 26.
Weller, P.F., et al., (1991) "Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1", *Proceedings of the National Academy of Sciences*, vol. 88, pp. 7430-7433.

Walsh, G.M., et al., (1991) "Human Eosinophil, But Not Neutrophil, Adherence to IL-1-Stimulated Human Umbilical Vascular Endothelial Cells Is $\alpha_4\beta_1$ (Very Late Antigen-4) Dependent", *J. Immunol.*, vol. 146, pp. 3419-3423.
Bochner, B.S., et al., (1991) "Adhesion of Human Basophils, Eosinophils, and Neutrophils to Interleukin 1-activated Human Vascular Endothelial Cells: Contributions of Endothelial Cell Adhesion Molecules", *J. Exp. Med.*, vol. 173, pp. 1553-1556.

Dobrina, A., et al., (1991) "Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells", *J. Clin. Invest.*, vol. 88, pp. 20-26.

Pulido, R., et al., (1991) "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activated Mediated by the Human Integrin VLA-4", *J. Biol. Chem.*, vol. 266, No. 16, pp. 10241-10245.

Gundel, R.H., et al., (1991) "Endothelial Leukocyte Adhesion Molecule-1 Mediates Antigen-induced Acute Airway Inflammation and Late-phase Airway Obstruction in Monkeys", *J. Clin. Invest.*, vol. 88, pp. 1407-1411.

Parmentier, S., et al., (1991) "Role of Glycoprotein IIa (beta subunit of very late activation antigens) in platelet functions", *Chemical Abstract*, vol. 115, No. 23, Abst. # 252 791h.

Onish, R., et al., (1991) "A monoclonal antibody, 2H7, which defines a new very late activation antigen, inhibits IL-2-mediated cell proliferation", *Chemical Abstract*, vol. 114, No. 9, Abst. #79 730s.

Sears, M.R., (1990) "Epidemiology of Asthma", in *Asthma as an Inflammatory Disease*, P. O'Byrne Ed., Marcel Dekker, Inc.; New York, pp. 15-48.

Cockcroft, D.W., (1990) "Atopy and Asthma", in *Asthma as an Inflammatory Disease*, P. O'Byrne Ed., Marcel Dekker, Inc.; New York, pp. 103-125.

Cuss, F.M.C., (1990) "The Pharmacology of Antiasthma Medications", in *Asthma as an Inflammatory Disease*, P. O'Byrne Ed., Marcel Dekker, Inc.; New York, pp. 199-250.

O'Byrne, P.M., (1990) "Airway Inflammation and Asthma", in *Asthma as an Inflammatory Disease*, P. O'Byrne Ed., Marcel Dekker, Inc.; New York, pp. 143-157.

Hogg, J.C., (1990) "Pathology of Asthma", in *Asthma as an Inflammatory Disease*, P. O'Byrne Ed., Marcel Dekker, Inc.; New York, pp. 1-13.

Chung, K.F., (1990) "Inflammatory Mediators in Asthma", in *Asthma as an Inflammatory Disease*, P. O'Byrne Ed., Marcel Dekker, Inc.; New York, pp. 159-183.

(List continued on next page.)

Primary Examiner—Lila Feisce

Assistant Examiner—Phillip Gambel

Attorney, Agent, or Firm—Louis Myers, Esq.; Lahive & Cockfield, LLP

[57]

ABSTRACT

A method for the treatment of asthma is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a protein expressed on the surface of certain leukocytes such as eosinophils.

22 Claims, 12 Drawing Sheets